// App-Quantinova.ai

M4189 2016 AHA : Reduced Risk of Hyperkalemia in Heart Failure Patients Treated With an MRA and Sacubitril/Valsartan Compared With Enalapril: The PARADIGM-HF Trial

Researchers

Presenter

  • Milton Packer

Principal Investigators

  • Brian Claggett

  • Orly Vardeny

  • Michael Zile

  • Karl Swedberg

  • Jean Rouleau

  • Victor Shi

  • Martin Lefkowitz

  • John McMurray

Medical Centers

  • Univeristy of Gothenburg, Gothenburg, Sweden.

  • University of Glasgow, Glasgow, United Kingdom

  • Medcl Univ of South Carolina, Charleston, SC

  • Univeristy of Wisconsin, Madison, WI

  • Brigham and Womens Hospital/Harvard University, Boston, MA

  • Baylor Univ Dallas, Dallas, TX

  • University of Montreal, Montreal, QC, Canada

Locations

  • United States

  • Canada

  • United Kingdom

  • Sweden

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Heart failure with reduced ejection fraction

  • Hyperkalemia

Biomarkers

  • N/A

Drug/Treatment

  • Sacubitril/valsartan

  • Enalapril maleate

  • Valsartan

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved